Antidepressants for bipolar disorder: A meta-analysis of randomized, double-blind, controlled trials

Neural Regeneration Research

Volumn 8, Issue 31, 2013, Pages 2962-2974

  Zhang, Ying Li ^a,b   Yang, Huan ^a   Yang, Shi Chang ^b   Liang, Wei ^b   Dai, Ping ^c   Wang, Chang Hong ^b   Zhang, Ya Lin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b XINXIANG MEDICAL UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Antidepressant; Bipolar depression; Bipolar disorder; Evidence based medicine; Grants supported paper; Meta analysis; Neural regeneration; Neuroregeneration; Response; Suicidality; Switching to mania

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CHLORAL HYDRATE; CITALOPRAM; FLUOXETINE; IMIPRAMINE; LAMOTRIGINE; LITHIUM; LORAZEPAM; MOCLOBEMIDE; MOOD STABILIZER; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SULPIRIDE; TRANYLCYPROMINE; TRAZODONE; VALPROATE SEMISODIUM; VALPROIC ACID; ZALEPLON; ZOLPIDEM; ZOPICLONE; ANTIDEPRESSANT AGENT;

ARTICLE; BIPOLAR DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFORMATION PROCESSING; MANIA; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SUICIDAL BEHAVIOR; TREATMENT RESPONSE; DRUG USE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HAMILTON DEPRESSION RATING SCALE; HYPERGLYCEMIA; HYPERLIPIDEMIA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; YOUNG MANIA RATING SCALE;

EID: 84889058304     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2013.31.009     Document Type: Article

References (62)

1. Bruffaerts R, Vilagut G, Demyttenaere K, et al. Role of common mental and physical disorders in partial disability around the world. Br J Psychiatry. 2012;200(6):454-461.
2. Kenneson A, Funderburk JS, Maisto SA. Risk factors for secondary substance use disorders in people with childhood and adoles-cent-onset bipolar disorder: Opportunities for prevention. Compr Psychiatry. in press.
3. Undurraga J, Baldessarini RJ, Valenti M, et al. Suicidal risk factors in bipolar I and II disorder patients. J Clin Psychiatry. 2012;73(6):778-782.
4. Grande I, Goikolea JM, de Dios C, et al. Occupational disability in bipolar disorder: analysis of predictors of being on severe disablement benefit (PREBIS study data). Acta Psychiatr Scand. 2013;127(5):403-411.
5. Ebmeier KP. Managing bipolar disorder in primary care. Practitioner. 2010;254(1729):19-22.
6. Ketter TA. Diagnostic features, prevalence, and impact of bipolar disorder. J Clin Psychiatry. 2010;71(6):e14.
7. Ferrari AJ, Saha S, McGrath JJ, et al. Health states for schizophrenia and bipolar disorder within the Global Burden of Disease 2010 Study. Popul Health Metr. 2012; 10(1):16.
8. Magalhaes PV, Kapczinski F, Nierenberg AA, et al. Illness burden and medical comorbidity in the Systematic Treatment Enhancement Program for Bipolar Disorder. Acta Psychiatr Scand. 2012;125(4):303-308.
9. Angst J, Gamma A, Bowden CL, et al. Evidence-based definitions of bipolar-I and bipolar-II disorders among 5,635 patients with major depressive episodes in the Bridge Study: validity and comorbidity. Eur Arch Psychiatry Clin Neurosci. in press.
10. th ed. Washington, DC: American Psychiatric Association. 2000.
11. Baek JH, Park DY, Choi J, et al. Differences between bipolar I and bipolar II disorders in clinical features, comorbidity, and family history. J Affect Disord. 2011;131(1-3):59-67.
12. Yatham LN, Fountoulakis KN, Rahman Z, et al. Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode. J Affect Disord. 2013;147(1-3):365-372.
13. Kemp DE, Hert MD, Rahman Z, et al. Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine. J Affect Disord. 2013; 148(1):84-91.
14. Fornaro M, Martino M, De Pasquale C, et al. The argument of antidepressant drugs in the treatment of bipolar depression: mixed evidence or mixed states? Expert Opin Pharmacother. 2012;13(14):2037-2051.
15. Grof P, Duffy A, Alda M, et al. Lithium response across generations. Acta Psychiatr Scand. 2009;120(5):378-385.
16. Cipriani A, Rendell J, Geddes JR. Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis. J Psychopharmacol. 2010;24(12): 1729-1738.
17. Sanford M, Keating GM. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs. 2012; 26(5):435-460.
18. Fountoulakis KN, Kasper S, Andreassen O, et al. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci. 2012;262 Suppl 1:1-48.
19. Citrome L. Olanzapine-fluoxetine combination for the treatment of bipolar depression. Expert Opin Pharmacother. 2011;12(17):2751-2758.
20. Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry. 2011;72(3):356-366.
21. Frankle W, Perlis R, Deckersbach T, et al. Bipolar depression: relationship between episode length and antidepressant treatment. Psychol Med. 2002;32(8):1417-1423.
22. Malhi GS, Tanious M, Das P, et al. The science and practice of lithium therapy. Aust N Z J Psychiatry. 2012; 46(3):192-211.
23. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225-255.
24. Amsterdam JD, Wang G, Shults J. Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapy. Acta Psychiatr Scand. 2010; 121(3):201-208.
25. Amsterdam JD, Luo L, Shults J. Efficacy and mood conversion rate during long-term fluoxetine v. lithium monotherapy in rapid-and non-rapid-cycling bipolar II disorder. Br J Psychiatry. 2013;202(4):301-306.
26. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1-44.
27. Nivoli AM, Colom F, Murru A, et al. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord. 2011;129(1-3):14-26.
28. Musetti L, Del Grande C, Marazziti D, et al. Treatment of bipolar depression. CNS Spectr. 2013:1-11.
29. Podawiltz A. A review of current bipolar disorder treatment guidelines. J Clin Psychiatry. 2012;73(3):e12.
30. Walpoth-Niederwanger M, Kemmler G, Grunze H, et al. Treatment patterns in inpatients with bipolar disorder at a psychiatric university hospital over a 9-year period: focus on mood stabilizers. Int Clin Psychopharmacol. 2012; 27(5):256-266.
31. Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry. 2011;72(2):156-167.
32. Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161(9): 1537-1547.
33. Wilson M. DSM-III and the transformation of American psychiatry: a history. Am J Psychiatry. 1993;150(3):399-410.
34. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
35. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.
36. Kirschenfeld JJ. A community medical education program in Montgomery. J Med Assoc State Ala. 1979;48(9):7-8.
37. Steinberg M. Interviewers Guide to the Structured Clinical Interview for DSM-IV Dissociative Disorders (SCID-D). Washington, DC: American Psychiatric Press. 1994.
38. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1[updated September 2008]. NewYork: John Wiley & Sons, Inc. 2008.
39. Amsterdam JD, Shults J. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol. 2005;20(5):257-264.
40. Amsterdam JD, Shults J. A-comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction. J Affect Disord. 2005;87(1): 121-130.
41. Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry. 2010;167(7):792-800.
42. Bocchetta A, Bernardi F, Burrai C, et al. A double-blind study of L-sulpiride versus amitriptyline in lithium-maintained bipolar depressives. Acta Psychiatr Scand. 1993; 88(6):434-439.
43. Cohn JB, Collins G, Ashbrook E, et al. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol.1989;4(4): 313-322.
44. Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry. 1991;148(7):910-916.
45. McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71(2):163-174.
46. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158(6):906-912.
47. Pilhatsch M, Wolf R, Winter C, et al. Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: a reanalysis of a randomized, double-blind study. J Affect Disord. 2010; 126(3):453-457.
48. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711-1722.
49. Schaffer A, Zuker P, Levitt A. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord. 2006; 96(1-2):95-99.
50. Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry. 2004;65(12):1715-1719.
51. Silverstone T. Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatr Scand. 2001;104(2):104-109.
52. Young LT, Joffe RT, Robb JC, et al. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry. 2000; 157(1):124-126.
53. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006;189: 124-131.
54. Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006;67(7):1025-1033.
55. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I de-pression. Arch Gen Psychiatry. 2003;60(11):1079-1088.
56. Grossman F, Potter WZ, Brown EA, et al. A double-blind study comparing idazoxan and bupropion in bipolar depressed patients. J Affect Disord. 1999;56(2-3):237-243.
57. Amsterdam JD, Shults J. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J Clin Psychopharmacol. 2008;28(2):171-181.
58. Tamayo JM, Sutton VK, Mattei MA, et al. Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. J Clin Psychopharmacol. 2009;29(4):358-361.
59. Bond DJ, Noronha MM, Kauer-Sant, Anna M, et al. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry. 2008;69(10):1589-1601.
60. Wagner KD, Asarnow JR, Vitiello B, et al. Out of the black box: treatment of resistant depression in adolescents and the antidepressant controversy. J Child Adolesc Psychopharmacol. 2012;22(1):5-10.
61. Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ. 2009;180(3):291-297.
62. Valluri S, Zito JM, Safer DJ, et al. Impact of the 2004 Food and Drug Administration pediatric suicidality warning on antidepressant and psychotherapy treatment for newonset depression. Med Care. 2010;48(11):947-954.